Quick Summary — ARAY scores higher on quality with 4.3/10 vs ALMR's 1.7/10. ALMR trades at $20.51 while ARAY trades at $0.39. Both analyzed daily using SEC EDGAR data across 13 institutional models.
ARAY scores higher with a 4.3/10 quality rating vs ALMR's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
ALMR currently trades at $20.51 while ARAY trades at $0.39. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily for both companies.
ALMR earns a Quality of Company score of 1.7/10 compared to ARAY's 4.3/10. This moderate difference suggests one company has an edge in fundamental quality, though both may offer investment merit depending on valuation. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.
Review the value trap analysis for both ALMR and ARAY to assess whether apparent undervaluation reflects genuine opportunity or hidden fundamental risk.
Both ALMR and ARAY operate in Medical Devices, which has 10 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).
11 hidden models compare ALMR vs ARAY differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.
Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day
See All 13 Models — $0.90/dayWe don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.